INTRODUCTION: The cannabinoid receptor type 2 (CB(2)) is an important target for development of drugs and imaging agents for diseases, such as neuroinflammation, neurodegeneration and cancer. Recently, we reported synthesis and results of in vitro receptor binding of a focused library of fluorinated 2-oxoquinoline derivatives as CB(2) receptor ligands. Some of the compounds demonstrated to be good CB(2)-specific ligands with Ki values in the nanomolar to subnanomolar concentrations; therefore, we pursued the development of their (18)F-labeled analogues that should be useful for positron emission tomography (PET) imaging of CB(2) receptor expression. Here, we report the radiosynthesis of two (18)F-labeled 2-oxoquinoline derivatives and the preliminary in vitro and ex vivo evaluation of one compound as a CB(2)-specific radioligand. METHODS: 4-[(18)F]fluorobenzyl amine [(18)F]-3 was prepared by radiofluorination of 4-cyano-N,N,N-trimethylanilinium triflate salt followed by reduction with LiAlH(4) and then coupled with acid chlorides 11 and 12 to afford [(18)F]-13 and [(18)F]-14. In vitro CB(2) receptor binding assay was performed using U87 cells transduced with CB(2) and CB(1) receptor. Ex vivo autoradiography was performed with [(18)F]-14 on spleen and on CB(2)- and CB(1)-expressing and wild-type U87 subcutaneous tumors grown in mice. RESULTS: The radiochemical yields of [(18)F]-13 and [(18)F]-14 were 10%-15.0% with an average of 12% (n=10); radiochemical purity was >99% with specific activity 1200 mCi/μmol. The dissociation constant Kd for [(18)F]-14 was 3.4 nM. Ex vivo autoradiography showed accumulation of [(18)F]-14 in the CB(2)-expressing tumor. CONCLUSION: Two new [(18)F]-labeled CB(2) ligands have been synthesized. Compound [(18)F]-14 appears to be a potential PET imaging agent for the assessment of CB(2) receptor expression; however, poor solubility restrain its use in vivo.
INTRODUCTION: The cannabinoid receptor type 2 (CB(2)) is an important target for development of drugs and imaging agents for diseases, such as neuroinflammation, neurodegeneration and cancer. Recently, we reported synthesis and results of in vitro receptor binding of a focused library of fluorinated 2-oxoquinoline derivatives as CB(2) receptor ligands. Some of the compounds demonstrated to be good CB(2)-specific ligands with Ki values in the nanomolar to subnanomolar concentrations; therefore, we pursued the development of their (18)F-labeled analogues that should be useful for positron emission tomography (PET) imaging of CB(2) receptor expression. Here, we report the radiosynthesis of two (18)F-labeled 2-oxoquinoline derivatives and the preliminary in vitro and ex vivo evaluation of one compound as a CB(2)-specific radioligand. METHODS:4-[(18)F]fluorobenzyl amine [(18)F]-3 was prepared by radiofluorination of 4-cyano-N,N,N-trimethylanilinium triflate salt followed by reduction with LiAlH(4) and then coupled with acid chlorides 11 and 12 to afford [(18)F]-13 and [(18)F]-14. In vitro CB(2) receptor binding assay was performed using U87 cells transduced with CB(2) and CB(1) receptor. Ex vivo autoradiography was performed with [(18)F]-14 on spleen and on CB(2)- and CB(1)-expressing and wild-type U87 subcutaneous tumors grown in mice. RESULTS: The radiochemical yields of [(18)F]-13 and [(18)F]-14 were 10%-15.0% with an average of 12% (n=10); radiochemical purity was >99% with specific activity 1200 mCi/μmol. The dissociation constant Kd for [(18)F]-14 was 3.4 nM. Ex vivo autoradiography showed accumulation of [(18)F]-14 in the CB(2)-expressing tumor. CONCLUSION: Two new [(18)F]-labeled CB(2) ligands have been synthesized. Compound [(18)F]-14 appears to be a potential PET imaging agent for the assessment of CB(2) receptor expression; however, poor solubility restrain its use in vivo.
Authors: Alysia N Lozano-Ondoua; Courtney Wright; Anna Vardanyan; Tamara King; Tally M Largent-Milnes; Mark Nelson; Juan Miguel Jimenez-Andrade; Patrick W Mantyh; Todd W Vanderah Journal: Life Sci Date: 2010-02-20 Impact factor: 5.037
Authors: Caroline Vandeputte; Nele Evens; Jaan Toelen; Christophe M Deroose; Barbara Bosier; Abdelilah Ibrahimi; Anke Van der Perren; Rik Gijsbers; Peter Janssen; Didier M Lambert; Alfons Verbruggen; Zeger Debyser; Guy Bormans; Veerle Baekelandt; Koen Van Laere Journal: J Nucl Med Date: 2011-06-16 Impact factor: 10.057
Authors: Nashaat Turkman; Aleksander Shavrin; Roman A Ivanov; Brian Rabinovich; Andrei Volgin; Juri G Gelovani; Mian M Alauddin Journal: Bioorg Med Chem Date: 2011-08-05 Impact factor: 3.641
Authors: Andrew G Horti; Yongjun Gao; Hayden T Ravert; Paige Finley; Heather Valentine; Dean F Wong; Christopher J Endres; Alena V Savonenko; Robert F Dannals Journal: Bioorg Med Chem Date: 2010-05-25 Impact factor: 3.641
Authors: Nele Evens; Giulio G Muccioli; Nele Houbrechts; Didier M Lambert; Alfons M Verbruggen; Koen Van Laere; Guy M Bormans Journal: Nucl Med Biol Date: 2009-03-26 Impact factor: 2.408
Authors: Nele Evens; Barbara Bosier; Brian J Lavey; Joseph A Kozlowski; Peter Vermaelen; Luc Baudemprez; Roger Busson; Didier M Lambert; Koen Van Laere; Alfons M Verbruggen; Guy M Bormans Journal: Nucl Med Biol Date: 2008-10 Impact factor: 2.408
Authors: Enrico Raffaele Fantoni; Diego Dal Ben; Simonetta Falzoni; Francesco Di Virgilio; Simon Lovestone; Antony Gee Journal: EJNMMI Res Date: 2017-04-04 Impact factor: 3.138
Authors: Linjing Mu; Roger Slavik; Adrienne Müller; Kasim Popaj; Stjepko Cermak; Markus Weber; Roger Schibli; Stefanie D Krämer; Simon M Ametamey Journal: Pharmaceuticals (Basel) Date: 2014-03-06
Authors: Rodrigo Teodoro; Rareş-Petru Moldovan; Corinna Lueg; Robert Günther; Cornelius K Donat; Friedrich-Alexander Ludwig; Steffen Fischer; Winnie Deuther-Conrad; Bernhard Wünsch; Peter Brust Journal: Org Med Chem Lett Date: 2013-09-24
Authors: Muneer Ahamed; Daisy van Veghel; Christoph Ullmer; Koen Van Laere; Alfons Verbruggen; Guy M Bormans Journal: Front Neurosci Date: 2016-09-22 Impact factor: 4.677